Athens Medical Centre (FRA:ACS) Growth Rank: 2 (As of Aug. 20, 2026) — 50% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ACS Athens Medical Centre SA FRA:ACS
56 GF Score
Price €1.44
GF Value €1.80
! 8 Warning Signs
View Full Analysis

What is Athens Medical Centre Growth Rank?

Athens Medical Centre FRA:ACS 56 Growth Rank is 2 as of Aug. 20, 2026, which is 50% below its 10-year median of 4.00. GuruFocus rates FRA:ACS with a GF Score™ of 56/100 and a GF Value™ of €1.80. The stock has 8 warning signs investors should review.

Athens Medical Centre has the Growth Rank of 2.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Athens Medical Centre Growth Rank Related Terms

FRA:ACS vs HCA, THC, DVA: Growth Rank Comparison

For the Medical Care Facilities subindustry, Athens Medical Centre's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Athens Medical Centre Growth Rank vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Athens Medical Centre's Growth Rank distribution charts can be found below:

* The bar in red indicates where Athens Medical Centre's Growth Rank falls into.


FRA:ACS
56GF Score
Athens Medical Centre SA FRA:ACS
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 2 mean?
Athens Medical Centre (FRA:ACS) has a Growth Rank of 2 as of Aug. 20, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Athens Medical Centre and its competitors. This is 50% below median its historical median of 4.00. Over the past decade, Athens Medical Centre's Growth Rank has ranged from 2.00 to 7.00.
Is Athens Medical Centre's Growth Rank too high?
Athens Medical Centre's current Growth Rank of 2 is 50% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. Overall, Athens Medical Centre has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Athens Medical Centre's Growth Rank compare to HCA and THC?
Athens Medical Centre's Growth Rank of 2 can be compared against companies in the Healthcare Providers & Services industry. Historically, Athens Medical Centre's own Growth Rank has ranged from 2.00 to 7.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Healthcare Providers & Services company?
A good Growth Rank depends on the Healthcare Providers & Services industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Athens Medical Centre and its competitors. Athens Medical Centre's current Growth Rank is 2, which is 50% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Athens Medical Centre stock overvalued right now?
Athens Medical Centre (FRA:ACS) has a current Growth Rank of 2. The stock's GF Value™ is €1.80, compared to a current price of €1.44 — trading 20% below its estimated fair value. The current Growth Rank is 2, which is 50% below median its 10-year median of 4.00. Athens Medical Centre's overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Athens Medical Centre (FRA:ACS), the current Growth Rank is 2 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Athens Medical Centre (FRA:ACS) Overvalued in 2026?

Based on GuruFocus' analysis, Athens Medical Centre stock appears to be undervalued. The current stock price of €1.44 is trading 20% below its estimated GF Value™ of €1.80.

Key valuation signals for FRA:ACS:

  • Growth Rank: 2 (50% below median its 10-year median of 4.00)
  • GF Value™: €1.80 vs. price of €1.44 (20% below fair value)
  • GF Score™: 56/100 with 8 warning signs

No single metric tells the full story. See the FRA:ACS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Athens Medical Centre Business Description

Other Exchanges IATR:Greece
Address 5-7 Distomou Street Maroussi, Athens, GRC, 15125
Athens Medical Centre SA engages in the provision of healthcare services. It includes medical research and methods of treatment, training, and selection of executives and staff on behalf of the hospitals and importation of medical tools, instruments, machinery, and automated devices for the hospitals. Its offering includes medical services in such specializations as pathology, cardiology, general surgery, plastic and vascular surgery, orthopedic, physiotherapy, ophthalmology, urology, neurosurgery, thoracic, pediatric, dermatology, endocrinology and stomatology. The company operates in Domestic healthcare service, Healthcare service provided abroad (Romania) and Sale of medical tools & sanitary/health equipment segment.
56GF Score

Get the complete analysis for FRA:ACS

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.44
Price
€1.80
GF Value